Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (RRMM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Large-scale testing (Phase 3)Not Yet RecruitingNCT07728188
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AbbVie 520
Very early researchNot Yet RecruitingNCT07322159
What this trial is testing

IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 12
Very early researchNot Yet RecruitingNCT07727668
What this trial is testing

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaRelapsed/Refractory Multiple Myeloma
Shambavi Richard 22
Testing effectiveness (Phase 2)UnknownNCT04891744
What this trial is testing

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Who this might be right for
Multiple Myeloma
Li Zheng 48
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Testing effectiveness (Phase 2)Looking for participantsNCT07455851
What this trial is testing

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 150
Early research (Phase 1)Not Yet RecruitingNCT07831122
What this trial is testing

Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Canadian Myeloma Research Group 108
Testing effectiveness (Phase 2)Looking for participantsNCT06518551
What this trial is testing

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Who this might be right for
MyelomaMultiple MyelomaRefractory Multiple Myeloma
Omar Nadeem, MD 49
Early research (Phase 1)UnknownNCT04677452
What this trial is testing

Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 24
Early research (Phase 1)Ended earlyNCT04401020
What this trial is testing

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Who this might be right for
Neoplasm Malignant
Sanofi 47
Very early researchActive Not RecruitingNCT05838131
What this trial is testing

Study of CT071 Injection in RRMM or PPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
Shanghai Changzheng Hospital 20
Not applicableNot Yet RecruitingNCT07320326
What this trial is testing

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Who this might be right for
TCE-RRMM
Peking University People's Hospital 159
Testing effectiveness (Phase 2)Looking for participantsNCT07637578
What this trial is testing

Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in Relapse+1 more
SCRI Development Innovations, LLC 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT07084896
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 106
Testing effectiveness (Phase 2)Study completedNCT06212596
What this trial is testing

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
University of Leeds 66
Early research (Phase 1)Active Not RecruitingNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 100
Testing effectiveness (Phase 2)Ended earlyNCT03639610
What this trial is testing

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

Who this might be right for
Renal ImpairmentMultiple Myeloma
Oncopeptides AB 35
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Early research (Phase 1)Study completedNCT04177823
What this trial is testing

Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 6
Next Page